Healthcare
Live Price
Offline$145.76
+1.56% today
1Y Change
-52.62%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Insulet Corporation (PODD) is a Healthcare stock with a market cap of $12.12B and listed on NASDAQ. The stock last traded around $145.76 and down 52.6% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +30.7%, EPS growth of -41.2%, a dividend yield of 0.0%. What stands out right now is revenue +30.7%, EPS -41.2%, free cash flow +23.7% with operating margin 17.5% and ROIC 13.6%. Valuation already assumes a fairly strong business story at P/E 49.8 and price/sales 4.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PODD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PODD
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PODD Max Drawdown
-59.63%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PODD and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.1B
-15.8% YoY
FY Net Income
$16.8M
+265.2% YoY
Free Cash Flow
-$190.8M
-398.2% YoY
Revenue Growth
+30.7%
EPS Growth
-41.2%
Gross Margin
71.6%
Net Margin
9.1%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.7B | 2.1B | 1.7B | 1.3B | 1.1B |
| Gross Profit | 1.9B | 1.4B | 1.2B | 806M | 752M |
| Operating Income | 474M | 309M | 220M | 38M | 126M |
| EBITDA | 587M | 424M | 324M | 109M | 140M |
| Net Income | 247M | 418M | 206M | 5M | 17M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 716M | 953M | 651M | 624M | 792M |
| Total Assets | 3.2B | 3.1B | 2.6B | 2.3B | 2.0B |
| Total Liabilities | 1.7B | 1.9B | 1.9B | 1.8B | 1.5B |
| Shareholder Equity | 1.5B | 1.2B | 733M | 476M | 556M |
| Total Debt | 1.1B | 1.4B | 1.4B | 1.4B | 1.3B |
| Net Debt | 335M | 469M | 798M | 809M | 495M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
68M
-157.2% YoY
Capital Expenditures
123M
+22.0% YoY
Free Cash Flow
191M
-398.2% YoY
Key ratios
Gross Margin
71.6%
Operating Margin
17.5%
Net Margin
9.1%
ROE
17.4%
Debt / Equity
0.69x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.